By 2017, the global electrophysiology mapping and ablation devices market is likely to achieve a value of $2.1 billion, according to a new report on companiesandmarkets.com. An ageing population, an increased number of diagnoses and several clinical studies have encouraged market growth.
Electrophysiology Mapping and Ablation Devices: A Global Strategic Business Report
The US is the largest market for electrophysiology mapping and ablation devices. Europe is a long way behind, but rapid growth is expected in Asia-Pacific. The largest global product segment is Electrophysiology Ablation Catheters, but the Electrophysiology Mapping Catheters segment will grow more quickly in all countries but the US.
Irrigated ablation catheters are becoming more popular with surgeons than non-irrigated options, and manual device manoeuvre is far more prevalent than robotic and remote magnetic guidance techniques. Using robotic navigation technologies in combination with ablation procedures is likely to enhance growth in the electrophysiology mapping and ablation devices markets, as are improvements to ablation catheter design, and remote catheter navigation systems. Furthermore, a number of new products for AF ablation are awaiting approval in the US, and are expected to increase the market value upon their launch.
Many pharmacological arrhythmia treatments have low efficacy ratings and unpleasant side effects, therefore advanced technologies and improved awareness of relevant procedures will drive a strong future for the electrophysiology mapping and ablation devices market.
In total, 24 market players are profiled in the electrophysiology mapping and ablation devices research report, including: AtriCure Inc; Boston Scientific Corp; Endosense SA; Medtronic Inc; Stereotaxis; Arrow International Inc; Biosense Webster Inc; C.R. Bard Inc; Hansen Medical Inc and St. Jude Medical Inc.
Researchers identify genes linked to muscle aging and sarcopenia